Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review)
- Authors:
- Published online on: February 19, 2020 https://doi.org/10.3892/ijo.2020.4990
- Pages: 1064-1074
Abstract
1. Introduction
Prostate cancer (PCa) and breast cancer (BCa) are two common types of malignant tumor with high mortality rates. According to recent statistical data, the number of new cases of PCa and BCa accounts for 7.1 and 11.6% of the total cancer cases worldwide, and the numbers of deaths from PCa and BCa account for 3.8 and 6.6% of all cancer deaths, respectively (1). Particularly in Asian countries like China, the incidences of PCa and BCa have been constantly increasing over the last two decades (2). Owing to the improved early diagnosis and advanced therapeutic strategies, the mortality rates of PCa and BCa have appreciably decreased. Unfortunately, the majority of patients eventually develop more aggressive malignant forms that are resistant to the most common treatments, leading to a poor prognosis (3,4). Thus, therapeutic resistance still poses a major challenge on the path to conquer PCa and BCa.
As sex hormone-related cancer types, PCa and BCa share a common feature; namely, that the interaction between sex hormones and hormone receptors is required to initiate tumorigenesis (5,6). In PCa, the androgen response is thought to be essential for tumorigenesis. Blockage of the interaction between androgen and the androgen receptor (AR) has been implicated in the induction of caspase-mediated apoptosis, as well as the inhibition of cell proliferation by altering cell cycling (7,8). Like androgen, estrogen is also essential for cell survival and proliferation, and estrogen receptor (ER) activation is recognized to play a pivotal role in BCa progression (9-11). Overall, heightened AR and ER activities are thought to contribute to the development of PCa and BCa through AR/ER-mediated signal transduction.
Since sex hormone responses are a key factor for the initiation of tumorigenesis in both PCa and BCa, hormone deprivation has become a common therapeutic option for the treatment of these two types of cancer. However, although most patients can gain certain therapeutic benefits from hormone therapies in the early stages, a large number of patients eventually acquire therapeutic resistance, leading to tumor recurrence and metastasis in hormone-free conditions (3,12). Overall, the therapeutic strategies for PCa and BCa are quite similar (Table I).
For patients with low- and intermediate-risk localized PCa, local treatment such as prostatectomy and radiotherapy are efficient to prevent distant organ metastasis (13-15). Additionally, radiotherapy plus hormone therapy has been applied to treat patients with high-risk locally advanced PCa, metastatic PCa that is unsuitable for surgery, or tumor recurrence after prostatectomy (13,15,16). Finally, chemotherapy with serious side-effects is still required to treat malignant PCa when hormone therapy is no longer effective (13,15). Notably, recent advanced targeted therapy and immunotherapy for inhibiting malignancy-associated molecules, as well as specific signaling pathways, have been successfully used to control hormone-refractory states (17,18). In BCa treatment, for patients with the early stages of BCa, after breast-conserving surgery or mastectomy, radiotherapy is essential to reduce the risk of recurrence (19,20). Generally, endocrino-therapy is the first-line treatment for ER-positive BCa (21). Ultimately, chemotherapy is essential in treating patients with metastatic BCa, including human epidermal growth factor receptor 2 (HER2)-positive BCa, high-risk luminal HER2-negative BCa and triple-negative BCa (TNBC) (22-24). Likewise, targeted therapy for inhibiting HER2 appears to efficiently treat malignant BCa (25). Immunotherapy also has also become a potent therapeutic approach to controlling BCa progression and reversing drug resistance (26).
Overall, hormone therapy is a powerful tool for the treatment of the early stages of AR-positive PCa or ER-positive BCa. Nevertheless, chemotherapy is necessary for treating late-stage disease that is resistant to hormone therapy. Unfortunately, advanced disease with a metastatic phenotype remains incurable, particularly life-threatening metastases to the bones or brain (27-30). Thus, more efficient targeted therapy and immunotherapy are needed to more effectively treat advanced PCa/BCa. To that end, the aim of the present review was to integrate research on the mechanism by which PCa or BCa gradually progresses to the AR/ER-negative genotype. Activation of the NF-κB pathway appears to play a central role in the progression of hormone-independent malignancies and in endocrinotherapy resistance; in particular, RelB is a key factor in sustaining NF-κB activity to replace the function of AR/ER.
2. Key ligand receptors in PCa and BCa tumorigenesis
The interaction between ligands and receptors is thought to be essential for normal physiological development, but also to be involved in cancer progression. Abnormal activation of AR/ER signaling uniquely contributes toward the tumorigenesis of PCa/BCa. Nevertheless, unlike PCa with AR alone, the progesterone receptor (PR) and HER2 are also important receptors, along with ER, in BCa.
Biological functions of AR and ER in PCa and BCa
As major sex hormone receptors, AR and ER belong to the nuclear receptor superfamily, which can be activated by multiple ligands including steroids, thyroid hormones and retinoic acid (31-33). AR and ER function as transcription factors in the regulation of downstream gene expression (8,34). The mechanisms of AR/ER-mediated transcriptional regulation are illustrated in Fig. 1. AR is expressed in both androgen-dependent and -independent PCa (5,33); it can be activated by various steroid hormones, particularly androgenic hormones including testosterone and dihydrotestosterone (35,36). Similar to AR, there exist both ERa and Erβ, which are responsive to estrogen activation (6). In general, AR/ER form heterodimers with heat shock proteins (HSPs) to remain in an inactive state in the cytosol. HSP is released when hormone ligands bind to AR/ER, and subsequently the hormone ligand-receptor complexes transfer into the nuclei as a dimer, and bind to androgen/estrogen response elements located in the enhancer regions of the downstream regulated genes (3,8,37). Additionally, many co-factors also participate in AR/ER-mediated transcriptional regulation by interacting with AR/ER (3,6,8,33,37). Accordingly, multiple endocrine therapeutic approaches focusing on the suppression of AR/ER activation have been frequently used to treat PCa and BCa. However, after the initial benefits received from the AR/ER-targeted treatment, the therapeutic efficacies are inevitably declined when patients develop more aggressive AR/ER-independent malignancies (7,33,34,38).
PR and HER2 in BCa
In addition to ER, PR is another important sex steroid hormone receptor for sexual maturation and gestation, whose function is also relevant to BCa progression (39-42). Notably, HER2, a typical proto-oncogene, has been recognized as a key factor for promoting high risk BCa through a steroid-independent signaling pathway (43-45). Thus, HER2 has become an important biomarker for BCa progression as well as a therapeutic target for ~30% of patients with BCa (44-46). Increasing evidence has demonstrated that downregulation of PR and/or upregulation of HER2 in BCa leads to the acquisition of endocrinotherapy resistance (41,43,44,47).
3. Mechanistic switch from AR/ER to NF-κB in PCa and BCa progression
The functional consequences of cell signaling modulation are mainly ascribed to gene transcriptional regulation in PCa and BCa progression (48,49). AR/ER-mediated transcriptional regulation is thought to be critical for the development of the early stages of PCa/BCa. Nevertheless, AR/ER function eventually declines in the late stages of malignant PCa/BCa, particularly as a consequences of hormone deprivation therapy (50,51). Notably, other transcription factors like NF-κB functionally take over AR/ER to substantially reprogram the cell transcriptome, sustaining PCa/BCa progression under hormone-free conditions (52-54).
NF-κB functional substitution of AR/ER
It is thought that NF-κB negatively regulates AR function by competing for transcriptional regulation (55). Previous studies have demonstrated that androgen-independent PCa exhibits higher constitutive NF-κB binding activity than its androgen-dependent counterpart. Tumor necrosis factor (TNF)a induces NF-κB activation via stimulation of inhibitor of NF-κB (IKK), which is inhibited as an androgen analogue (56). For example, prostate-specific antigen (PSA), a common PCa biomarker, is regulated by AR (57). However, NF-κB is also able to regulate PSA through binding to a kB response element located in the promoter region (52). Consistently, inhibition of NF-κB results in the suppression of castration-resistant prostate cancer (CRPC) xenograft tumor growth (58). Nevertheless, NF-κB also appears to positively regulate androgen receptor splicing variant (ARV) transactivation (59,60). Additionally, AR-negative PCa stem cells with high constitutive NF-κB activity promote tumor growth during androgen deprivation therapy, suggesting that NF-κB gradually substitutes AR during CRPC progression (61). Notably, AR activation results in the suppression of the canonical NF-κB pathway, but leads to upregulation of the noncanonical NF-κB pathway (61).
Likewise, NF-κB plays a key role in the promotion of estrogen-independent growth in both ER-positive and -negative BCa (62). In particular, the evidence of low NF-κB activation in ER-positive BCa cells and high NF-κB activation in ER-negative BCa cells indicates an inverse relationship between ER and NF-κB in BCa progression (53), suggesting that constitutive NF-κB activity is consistently increased during ER-independent BCa progression (63,64). Blockage of NF-κB activation efficiently inhibits proliferation and reverses therapeutic resistance in ER-negative cells (54). Mechanistically, NF-κB represses ER expression, and high levels of NF-κB can cause downregulation of ER (65). In particular, it has been noted that levels of RelB are inversely correlated with the status of ER in BCa cells (66). RelB can stimulate PR/SET domain 1, which represses ER expression by binding to the ER promoter (67). However, in some early-stage ER-positive BCa cells, NF-κB activation has been shown to recruit ER to p65/estrogen response element motifs, resulting in increased ER transcriptional responses (68,69). Taken together, these findings predict that NF-κB gradually replaces ER, from transcriptional cooperation in inflammatory BCa states to functional substitution in hormone refractory states. The activation of the NF-κB pathway in the progression of hormone-deprived aggressive PCa and BCa is depicted in Fig. 2.
NF-κB activation mechanism
NF-κB is involved in various biological processes, such as cell survival, proliferation, differentiation and the immune response (70). Members of the NF-κB family have a conserved Rel homology domain at their N-terminus, including RelA (p65), RelB, c-Rel, NF-κB1 (p50) and NF-κB2 (p52) (71,72). NF-κB activation is divided into the canonical NF-κB pathway and the noncanonical NF-κB pathway. In the canonical NF-κB pathway, stimulating ligands including the Toll-like superfamily, interleukin (IL)-l, TNF and other antigens interact with their receptors to recruit adaptors, such as TNF receptor associated factor (TRAF)2, TRAF3 and nuclear receptor subfamily 2 group C member 2, which activate the IκB kinase complex (IKKα, IKKβ and IKKγ/NEMO) to phosphorylate and then ubiquitinate IKBα, leading to p50:RelA dimer nuclear translocation (73,74). By contrast, in the activation of the noncanonical NF-κB pathway, NF-κB-induced kinase stimulates IKKα to phosphorylate pl00, resulting in the release of p52 and promoting p52:RelB nuclear translocation (75,76). However, evidence has shown that p50 can also dimerize with RelB to activate the noncanonical NF-κB pathway (76).
Role of the NF-κB pathway in malignant PCa development
The activation of NF-κB plays a crucial role in PCa progression. Ras (GTP binding protein) cooperates with NF-κB and acts as a signal scaffold for metastatic promotion in PCa (77). In this context, it is well documented that NF-κB-activated inflammation, including cytokines/chemokines, contributes to CRPC (61). For instance, androgen ablation results in regression of androgen-dependent PCa, in which IKKα-activated NF-κB increases cytokine production leading to androgen-free proliferation (78). Importantly, constitutive activation of NF-κB is highly associated with PCa resistance to both chemotherapy and radiotherapy (79).
Role of the NF-κB pathway in advanced BCa development
Mounting evidence highlights that NF-κB promotes BCa metastasis by activating the epithelial-mesenchymal transition (EMT) process, partially by upregulating IL-lβ and IL-6 (80). In malignant BCa, epidermal growth factor receptor is integrated with NF-κB in the activation of IL-l, which promotes the invasive capacity of BCa cells (8l). Additionally, IL-8 stimulates the PI3K-AKT-NF-κB signaling axis, which in turn upregulates integrin βl/β3 expression, leading to increased motility as well as enhanced chemoresistance and radioresistance in BCa cells (63). Furthermore, a previous study demonstrated that the NF-κB-controlled proinflammatory cytokine network is important for the maintenance of cancer stem cells in the regulation of BCa plasticity, suggesting that NF-κB-mediated cytokine activation is critical for the recurrence of BCa after hormone therapy (82).
4. NF-κB activation in endocrinotherapy resistance
Although most patients with PCa and BCa are responsive to endocrinotherapy initially, treatment resistance and tumor relapse remains a salient question in clinical supervision. Indeed, clinical outcomes indicate that hormone deprivation treatment somehow promotes the development of hormone-independent malignant tumor types (83,84). Accordingly, multiple mechanisms have been reported to be relevant to endocrinotherapy resistance, including activation of the NF-κB pathway (47,83-87). Notably, the TNF-a, WNT5A, PI3K-AKT, Ras-Raf-ERK and transforming growth factor (TGF)-β1-mitogen activated protein kinase (MAPK) signaling axes have been demonstrated to be important upstream signaling pathways of the NF-κB pathway in both PCa and BCa (47,85,86,88-92).
As a typical redox responsible transcription factor, NF-κB responds to stimulation with reactive oxygen species (ROS). In the regard, NADPH oxidase 4 leads to ROS production accompanied by mitochondrial respiration, thereby stimulating the NF-κB pathway (88). Anticancer drugs such as TNF-α and adriamycin adapt to increase ROS, in turn induce antioxidant enzymes like manganese superoxide dismutase (MnSOD) through NF-κB activation (88,89). The PI3K-AKT and Ras-Raf-ERK signaling axes have been shown to play pivotal roles in PCa/BCa progression by modulating NF-κB in substitution for AR/ER (47,85,86,90-95). In particular, the activation of the PI3K-AKT-NF-κB signaling axis has been well documented for the development of a hormone-independent phenotype as well as therapeutic resistance in both PCa and BCa (63,96,97). Notably, PI3K activation in PTEN-deficient PCa is a hallmark of an androgen-independent phenotype (17). The results of a previous study suggested a reciprocal feedback between the two oncogenic pathways (98). PI3K activation leads to repression of AR transcriptional output and, consistently, PI3K inhibition activates AR signaling. Conversely, AR inhibition promotes PI3K activity in PTEN-deficient PCa. Thus, combined AR and PI3K inhibition produces improved therapeutic responses (98). Since PI3K is a key upstream signaling molecule for activation of the NF-κB pathway, this finding mechanistically elucidated the inverse association between AR and the NF-κB pathway.
In addition, TGF-β1-induced p38-MAPK signaling upregulates IL-6 expression due to RelA activation (99-101). RalBP1-associated Eps domain-containing protein 2 mediates RelA activation, and was also shown to promote androgen-independent growth (102). Nevertheless, NF-κB has also been shown to cooperate with AR under androgen deprivation conditions; for instance, macrophage stimulating 1 receptor, a receptor tyrosine kinase, is able to activate NF-κB, which is sufficient to drive AR nuclear localization under androgen deprivation condition and support CRPC growth (103).
Notably, the canonical NF-κB pathway can actually induce the noncanonical NF-κB pathway, thereby sustaining high NF-κB activity (76,104). Additionally, several inducible agents have been demonstrated to directly activate the noncanonical NF-κB pathway. WNT5A from bone stromal cells induces bone morphogenetic protein 6 (BMP-6) via RelB activation; in turn, BMP-6 stimulates PCa cell proliferation via the interaction between Smad5 and β-catenin (28). In addition, WNT5A activates NF-κB signaling to induce MMP7 expression, thereby contributing to the invasion of TNBC cells (105). A decrease in chicken ovalbumin upstream promoter transcription factor II results in endocrinotherapy resistance in BCa cells by activating the noncanonical NF-κB pathway (106); whereas, fucoxanthin appears to be able to reverse BCa endocrinotherapy resistance by suppressing RelB activation (107). Overexpression of aryl hydrocarbon receptor (AhR) leads to the activation of RelB, in turn upregulating IL-8 expression in BCa cells (108,109). Ribonucleotide reductase M2 (RRM2) leads to increased RelB activity, thereby endowing tamoxifen resistance due to the upregulation of Bcl-2 in BCa cells (110). Overall, NF-κB functions as a master switch, changing PCa/BCa from an AR/ER-positive phenotype to an AR/ER-negative phenotype (Fig. 3).
5. Main NF-κB-regulated proteins in endocrinotherapy resistance
NF-κB regulates a series of genes relevant to endocrinotherapy resistance. Particularly, it has been widely recognized that both canonical and noncanonical NF-κB pathways are vital for resistance to hormone receptor-targeted treatment in PCa and BCa (52,53,58,60,111). As important NF-κB-regulated proteins, Bcl-2, cyclin D1, IL-6 and IL-8 appeared to be critical for endocrinotherapy resistance in both PCa and BCa. The main NF-κB regulated proteins associated with endocri- notherapy resistance are summarized in Fig. 4.
Effect of the canonical NF-κB pathway in PCa endocrinotherapy resistance
Bcl-2, an important antiapoptotic protein, was upregulated in response to ROS-mediated NF-κB activation, promoting therapeutic resistance (112). TNF-α-mediated RelA activation contributes to CRPC partially through upregulation of Bcl-2 (113). In addition, the activation of NF-κB results in upregulation of IL-6, leading to castration resistance (114). Induction of IL-6 is important for hormone resistance, which is positively regulated by the canonical NF-κB pathway, but negatively regulated by AP-1 (115). IL-8 also promotes the progression of CRPC through NF-κB activation (116). NF-κB-activated IL-4 has been shown to enhance AR function in PCa cells with an absence or low levels of androgen (117). Altogether, the feed-forward activation of NF-κB-cytokines/chemokines is essential for the appearance of CRPC (118). In androgen-refractory PCa, the activation of canonical NF-κB pathway significantly increases the disease-specific death due to AKT-mediated IKK phosphorylation (119). Furthermore, NF-κB-enhanced EMT upregulates Twist1 in response to AR inhibition, leading to CRPC (120).
Effect of the canonical NF-κB pathway in BCa endocrinotherapy resistance
Estrogen withdrawal leads to increased p50:RelA DNA binding activity and sustained estrogen-independent growth through upregulation of cyclin D1 and Bcl-3 (121). Moreover, NF-κB-mediated upregulation of cyclin D1, urokinase and vascular endothelial growth factor contributes to endocrino- therapy resistance in high-risk ER-positive BCa (122). Immediate early gene X-1 expression is stimulated by tamoxifen through the binding of NF-κB to the promoter (123). X-box binding protein 1 is a key factor for antiestrogen resistance, the expression of which is regulated by modulating RelA (124). In tamoxifen-resistant BCa cells, NF-κB activation results in an increase in IL-6 (125). In TNBC cells, the lipoprotein(a)-lysophosphatidic acid receptor 2-enhancer of zeste 2 polycomb repressive complex 2 subunit-NF-κB signaling cascade is required for the coordinated autocrine effect of IL-6 and IL-8 (126). As expected, Bcl-2 is upregulated by the canonical NF-κB pathway in response to tamoxifen (127). Similar to PCa, the activation of the PI3K-AKT-NF-κB signaling axis is highly associated with endocrinotherapy resistance in BCa (128).
Emerging role of the noncanonical NF-κB pathway in endocrinotherapy resistance
In contrast to the well-studied p50:RelA activation described above, the role of p52:RelB in cancer responses to treatment remains elusive. Indeed, the noncanonical NF-κB pathway exerts even more effects in metastasis and therapeutic resistance rather than in tumorigenesis. p52:RelB can activate AR-responsive genes, such as PSA and NKX3.1 (a prostate-specific tumor suppressor) in a ligand-independent manner, suggesting that the noncanonical NF-κB pathway also plays a supporting role in CRPC progression (129). In addition, p52:RelB activation increases PCa cell survival and proliferation by upregulating Bcl-xL and cyclin D1 (130-132). Moreover, p52:RelB activation contributes to resistance to AR-targeted therapies through regulation of multiple signaling pathways, such as by modulating AR (60), upregulating c-Myc-depen- dent heterogeneous nuclear RNA-binding protein A1 (133), and enhancing glucose flux to the glycolysis and pentose phosphate pathways (134). Consistent with PCa, RelB is also highly expressed in hormone therapy-resistant BCa cells (111). Fucoxanthin appears to be able to reverse hormone therapy resistance by suppressing p52:RelB (107). Overexpression of AhR and RRM2 leads to the activation of RelB, thereby endowing tamoxifen resistance due to the upregulation of Bcl-2 and IL-8 (111). MEK-mediated p52 activation is required for TNBC growth and drug resistance (135). Overexpression of HOXB13 (a homeobox protein) enhances RelB nuclear translocation and contributes to therapeutic resistance (136).
6. NF-κB as a target in PCa and BCa treatment
Since NF-κB contributes to endocrinotherapy resistance in PCa and BCa, NF-κB-targeted therapy has frequently been applied to enhance endocrinotherapy. Nitric oxide donors sensitize Trail-mediated apoptosis via inhibition of Bcl-xL through inactivation of NF-κB (137). IL-6, a NF-κB-regulated cytokine, contributes to androgen-independent PCa progression. Inhibition of IL-6 enhances the sensitivity of PCa to docetaxel (138). NF-κB activation in ARVs associated with CRPC leads to anti-androgen therapy resistance. Repression of NF-κB enhances the efficiency of hormone therapy (59). Notably, Wedelia chinensis herbal extract has been shown not merely to inhibit AR activity in androgen-dependent PCa, but also to suppress the expression of IKKα/β phosphorylation in hormone-independent PCa cells (139). In BCa, NSC35446, a hydrochloride salt compound, is able to inhibit anti-estrogenic tumor growth and reverse antiestrogen resistance by targeting NF-κB (140). Additionally, ivermectin reverses chemotherapeutic resistance via suppression of NF-κB-activated P-gp expression (141). Importantly, a number of compounds appear to efficiently treat both aggressive PCa and BCa via repression of NF-κB-mediated transcriptional activation. Curcumin, an inhibitor of the NF-κB canonical pathway, is able to inhibit the hormone-mediated invasion of BCa (142). The combination of curcumin and bicalutamide enhances the growth inhibition of androgen-independent PCa cells (143), while 1a,25-dihydroxyvitamin D3 has been reported to repress the NF-κB noncanonical pathway, which strongly reduces the growth of drug-resistant BCa cells and enhances the radiosensitivity of PCa cells (144,145). Parthenolide, a native compound that functions as an NF-κB repressor, has been shown to restore the sensitivity of tamoxifen to endocrine-resistant BCa cells and to enhance PCa cell radiosensitivity (146-148).
7. Conclusions and perspectives
Endocrinotherapy resistance and tumor relapse are major challenges in treating advanced PCa and BCa. The progression from hormone-dependence to hormone-independence has been widely recognized to be one of main causes of endocrinotherapy resistance. Therefore, the molecular basis for the failure of treatments targeting AR or ER has been well investigated. This review reorganized the molecular mechanisms underlining endocrinotherapy resistance and concluded that NF-κB is the most important transcription regulator in activating the expression of a series of genes, leading to the acquisition of the endocrinotherapy resistance. In the majority of cases, NF-κB functionally substitutes AR or ER in transcriptional regulation for sustaining tumor cell survival and proliferation, by activating a different set of genes when the efficacy of AR/ER-targeted treatments declines. It should be noted, however, the inverse association between AR/ER and NF-κB is not persistent during the progression of PCa and BCa; in particular, a few case studies have demonstrated that RelA can cooperate with AR in transcriptional regulation when androgen deprivation treatment fails (103). Additionally, although the NF-κB pathway is thought to serve as a key mechanism underlying endocrinotherapy resistance, other signaling pathways, such as Myc, Stat3 and Wnt, also play regulatory roles in the acquisition of therapeutic resistance. Furthermore, NF-κB also plays a crucial role in the radioresistance of PCa and BCa through upregulation of antioxidant and antiapoptotic proteins, including MnSOD and Bcl-2 (149).
The present review also outlined that several upstream signaling pathways engage to trigger the NF-κB pathway; in particular, PI3K-AKT upstream signaling activates the NF-κB pathway in response to oxidative stress and inflammatory stimulation. Importantly, the cytokine/chemokine-NF-κB signaling feed-forward loop is indispensable for the acquisition of endocrinotherapy resistance. It was recently concluded that TGF-β, IL-6, IL-8 and TNF-α are the most important cytokines associated with multidrug resistance in BCa (150). These four cytokines are typical NF-κB-regulated proteins, and increased levels of inflammation in turn activate the NF-κB pathway, which promotes endocrinotherapy resistance.
Distant organ metastasis associated with multidrug resistance precludes successful treatment. A myriad of studies have demonstrated that RelA-activated canonical NF-κB pathway is critical for cancer progression and therapeutic resistance (82,103,110,124,151-153). However, the effect of the RelB-activated noncanonical NF-κB pathway is underestimated. Indeed, RelA can upregulate RelB, leading to sustained long-term NF-κB activity in cancer progression (76). Since the function of RelA is essential for normal physiological development, the failure of anticancer treatment by targeting RelA may be caused by either low therapeutic efficacy or unexpected side effects. It has been demonstrated that RelB is uniquely expressed at a high level in advanced PCa, which contributes to therapeutic resistance (149,154). Accordingly, blockage of RelB nuclear translocation has the effect of reversing resistance to treatment in AR-negative PCa (155). Thus, the inactivation of the noncanonical NF-κB pathway may provide a promising approach to the treatment of advanced PCa and BCa when AR/ER-targeted therapeutic efficiency declines.
In summary, this review emphasized the importance of NF-κB in the acquisition of endocrinotherapy resistance in PCa and BCa, suggesting that inhibition of the NF-κB pathway may overcome endocrinotherapy resistance and should be beneficial in developing comprehensive treatment strategies to control malignant PCa and BCa. In addition to the well-documented canonical NF-κB pathway, the noncanonical NF-κB pathway remains to be fully elucidated. Emerging evidence predicts that RelB may exert an even greater effect than RelA on metastasis and therapeutic resistance, based on its capacity for maintaining NF-κB activity. Of further interest, therefore, is why and how the noncanonical NF-κB pathway contributes to cancer progression and therapeutic resistance. To that end, this review is expected to shed light on future in-depth investigations into NF-κB function to advance the treatment of PCa/BCa therapeutic resistance.
Funding
This work was supported by National Natural Science Foundation of China Research Grants (grant no. 81572742) and National Program Project for Precision Medicine in National Research and Development Plan, China (grant no. 2016YFC0905900), and the National Natural Science Foundation of China (grant nos. 81274158 and 81873131).
Availability of data and materials
Not applicable.
Authors' contributions
XW and YX conceived and wrote the review. XW, YF, WS, ZX and YZ collected and organized the literature. XW, XD and YX supervised the work and provided administrative, technical and material support. All authors read and approved the content of the review.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Acknowledgments
Not applicable.
References
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45. 2001. View Article : Google Scholar | |
|
Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, et al: Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 71:603–613. 2011. View Article : Google Scholar : | |
|
Debes JD and Tindall DJ: The role of androgens and the androgen receptor in prostate cancer. Cancer Lett. 187:1–7. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Duffy MJ: Estrogen receptors: Role in breast cancer. Crit Rev Clin Lab Sci. 43:325–347. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Balk SP and Knudsen KE: AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 6:e0012008. View Article : Google Scholar : PubMed/NCBI | |
|
Lamb AD, Massie CE and Neal DE: The transcriptional programme of the androgen receptor (AR) in prostate cancer. BJU Int. 113:358–366. 2014. View Article : Google Scholar | |
|
Russo J and Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 102:89–96. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yue W, Wang JP, Li Y, Fan P, Liu G, Zhang N, Conaway M, Wang H, Korach KS, Bocchinfuso W, et al: Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int J Cancer. 127:1748–1757. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Samavat H and Kurzer MS: Estrogen metabolism and breast cancer. Cancer Lett. 356:231–243. 2015. View Article : Google Scholar : | |
|
DeMichele A and Chodosh LA: 'Braking' the cycle of resistance in endocrine therapy for breast cancer. Clin Cancer Res. 21:4999–5001. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Horwich A, Parker C, de Reijke T and Kataja V; ESMO Guidelines Working Group: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6): vi106–vi114. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al European Association of Urology: EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 65:124–137. 2014. View Article : Google Scholar | |
|
Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, et al: Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 14:19–30. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al European Association of Urology: EAU guidelines on prostate cancer: Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 65:467–479. 2014. View Article : Google Scholar | |
|
Wise HM, Hermida MA and Leslie NR: Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond). 131:197–210. 2017. View Article : Google Scholar | |
|
Bilusic M, Madan RA and Gulley JL: Immunotherapy of prostate cancer: Facts and hopes. Clin Cancer Res. 23:6764–6770. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YJ, Jung SY and Kim K: Survival benefit of radiotherapy after surgery in de novo stage IV breast cancer: A population-based propensity-score matched analysis. Sci Rep. 9:85272019. View Article : Google Scholar : PubMed/NCBI | |
|
Yao Y, Chu Y, Xu B, Hu Q and Song Q: Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Med. 8:554–563. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, et al: Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol. 34:3069–3103. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Alvarez Lopez I, de la Haba Rodriguez J, Ruiz Simon A, Bellet Ezquerra M, Calvo Martinez L, Garcia Estevez L, Rodriguez Lescure A and Isla Casado D: SEOM (Spanish Society for Medical Oncology): SEOM clinical guidelines for the treatment of metastatic breast cancer. Clin Transl Oncol. 12:719–723. 2010. View Article : Google Scholar | |
|
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S and Cardoso F; Committee EG: ESMO Guidelines Committee: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26(Suppl 5): v8–v30. 2015. View Article : Google Scholar | |
|
Goetz Mp, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison Kh, Blair SL, Burstein HJ, Dang C, Elias ad, et al: NCCN guidelines insights: Breast cancer, version 3.2018. J Natl Compr Canc Netw. 17:118–126. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed S, Sami A and Xiang J: HER2-directed therapy: Current treatment options for HER2-positive breast cancer. Breast Cancer. 22:101–116. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Esteva FJ, Hubbard-Lucey VM, Tang J and Pusztai L: Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 20:e175–e186. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP and Puduvalli VK: Brain metastasis from prostate carcinoma: The M.D. Anderson Cancer Center experience. Cancer. 98:363–368. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lee GT, Kang DI, Ha YS, Jung YS, Chung J, Min K, Kim TH, Moon KH, Chung JM, Lee DH, et al: Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Br J Cancer. 110:1634–1644. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, et al: Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases. Clin Cancer Res. 25:2737–2744. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yao B, Wang J, Qu S, Liu Y, Jin Y, Lu J, Bao Q, Li L, Yuan H and Ma C: Upregulated osterix promotes invasion and bone metastasis and predicts for a poor prognosis in breast cancer. Cell Death Dis. 10:282019. View Article : Google Scholar : PubMed/NCBI | |
|
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al: The nuclear receptor superfamily: The second decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Girdler F and Brotherick I: The oestrogen receptors (ER alpha and ER beta) and their role in breast cancer: A review. Breast. 9:194–200. 2000. View Article : Google Scholar | |
|
Suzuki H, Ueda T, Ichikawa T and Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 10:209–216. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Carroll JS: Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. Eur J Endocrinol. 175:R41–R49. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Russell DW and Wilson JD: Steroid 5 alpha-reductase: Two genes/two enzymes. Annu Rev Biochem. 63:25–61. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Marcelli M and Cunningham GR: Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab. 84:3463–3468. 1999.PubMed/NCBI | |
|
Sommer S and Fuqua SA: Estrogen receptor and breast cancer. Semin Cancer Biol. 11:339–352. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Alluri PG, Speers C and Chinnaiyan AM: Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res. 16:4942014. View Article : Google Scholar : PubMed/NCBI | |
|
Mc Cormack O, Chung WY, Fitzpatrick P, Cooke F, Flynn B, Harrison M, Fox E, Gallagher E, McGoldrick A, Dervan PA, et al: Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: Progesterone receptor B hypermethylation in breast cancer. Breast Cancer Res Treat. 111:45–53. 2008. View Article : Google Scholar | |
|
Wang H, Lee EW, Zhou L, Leung PC, Ross DD, Unadkat JD and Mao Q: Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol. 73:845–854. 2008. View Article : Google Scholar | |
|
Wu X, Zhang X, Zhang H, Su P, Li W, Li L, Wang Y, Liu W, Gao P and Zhou G: Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer. Cancer Sci. 103:959–967. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Grimm SL, Hartig SM and Edwards DP: Progesterone receptor signaling mechanisms. J Mol Biol. 428:3831–3849. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dowsett M: Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer. 8:191–195. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kurokawa H and Arteaga CL: ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res. 9:511S–515S. 2003.PubMed/NCBI | |
|
Hsu JL and Hung MC: The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 35:575–588. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Järvinen TAH, Pelto-Huikko M, Holli K and Isola J: Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 156:29–35. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Fan W, Chang J and Fu P: Endocrine therapy resistance in breast cancer: Current status, possible mechanisms and overcoming strategies. Future Med Chem. 7:1511–1519. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ding J, Wang X, Zhang Y, Sang X, Yi J, Liu C, Liu Z, Wang M, Zhang N, Xue Y, et al: Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Ka inhibition through the transcriptional regulation of ERa. Cancer Lett. 440-441:54–63. 2019. View Article : Google Scholar | |
|
Blessing AM, Rajapakshe K, Reddy Bollu L, Shi Y, White MA, Pham AH, Lin C, Jonsson P, Cortes CJ, Cheung E, et al: Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. Autophagy. 13:506–521. 2017. View Article : Google Scholar : | |
|
McCartan D, Bolger jC, Fagan A, Byrne C, Hao Y, Qin L, McIlroy M, Xu J, Hill AD, Gaora pO, et al: Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res. 72:220–229. 2012. View Article : Google Scholar | |
|
Sahin I, Mega AE and Carneiro BA: Androgen receptor-independent prostate cancer: An emerging clinical entity. Cancer Biol Ther. 19:347–348. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CD and Sawyers CL: NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol. 22:2862–2870. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Eppenberger-Castori S, Eppenberger U and Benz CC: The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer. 12(Suppl 1): S37–S46. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Oida K, Matsuda A, Jung K, Xia Y, Jang H, Amagai Y, Ahn G, Nishikawa S, Ishizaka S, Jensen-Jarolim E, et al: Nuclear factor-KB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci Rep. 4:40572014. View Article : Google Scholar | |
|
Malinen M, Niskanen EA, Kaikkonen MU and Palvimo JJ: Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome. Nucleic Acids Res. 45:619–630. 2017. View Article : Google Scholar | |
|
Péant B, Diallo JS, Lessard L, Delvoye N, Le Page C, Saad F and Mes-Masson AM: Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer. Mol Cancer Res. 5:87–94. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan X, Cai C, Chen S, Chen S, Yu Z and Balk SP: Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 33:2815–2825. 2014. View Article : Google Scholar | |
|
Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, et al: NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol. 175:489–499. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW and Matusik RJ: Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene. 34:3700–3710. 2015. View Article : Google Scholar | |
|
Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP and Gao AC: NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants. Mol Cancer Ther. 12:1629–1637. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Staal J and Beyaert R: Inflammation and NF-kappaB signaling in prostate cancer: Mechanisms and clinical implications. Cells. 7:72018. View Article : Google Scholar | |
|
Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY and Van Laere SJ: The interaction between ER and NFkB in resistance to endocrine therapy. Breast Cancer Res. 14:2122012. View Article : Google Scholar | |
|
Shao N, Lu Z, Zhang Y, Wang M, Li W, Hu Z, Wang S and Lin Y: Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway. Cancer Lett. 364:165–172. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nakshatri H Jr, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 17:3629–3639. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Belguise K and Sonenshein GE: PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. J Clin Invest. 117:4009–4021. 2007.PubMed/NCBI | |
|
Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D and Sonenshein GE: Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol. 9:470–478. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Belguise K, O'Neill CF, Sanchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, et al: RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol. 29:3832–3844. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pradhan M, Baumgarten SC, Bembinster LA and Frasor J: CBP mediates NF-κB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter. Mol Cell Biol. 32:569–575. 2012. View Article : Google Scholar : | |
|
Frasor J, El-Shennawy L, Stender JD and Kastrati I: NFkB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Mol Cell Endocrinol. 418:235–239. 2015. View Article : Google Scholar | |
|
Zeligs KP, Neuman MK and Annunziata CM: Molecular pathways: The balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-kB signaling for cancer treatment. Clin Cancer Res. 22:4302–4308. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sun SC: Non-canonical NF-κB signaling pathway. Cell Res. 21:71–85. 2011. View Article : Google Scholar | |
|
Kastrati I, Siklos MI, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN, Thatcher GR and Frasor J: Dimethyl fumarate inhibits the nuclear factor kB pathway in breast cancer cells by covalent modification of p65 protein. J Biol Chem. 291:3639–3647. 2016. View Article : Google Scholar | |
|
Vrábel D, Pour L and Ševčíková S: The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 34:56–66. 2019. View Article : Google Scholar | |
|
Park MH and Hong JT: Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells. 5:52016. View Article : Google Scholar | |
|
Maubach G, Feige MH, Lim MCC and Naumann M: NF-kappaB-inducing kinase in cancer. Biochim Biophys Acta Rev Cancer. 1871:40–49. 2019. View Article : Google Scholar | |
|
Gray CM, Remouchamps C, McCorkell KA, Solt LA, Dejardin E, Orange JS and May MJ: Noncanonical NF-κB signaling is limited by classical NF-κB activity. Sci Signal. 7:ra132014. View Article : Google Scholar | |
|
Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, et al: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 16:286–294. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ammirante M, Luo JL, Grivennikov S, Nedospasov S and Karin M: B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 464:302–305. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mendonca MS, Turchan WT, Alpuche ME, Watson CN, Estabrook NC, Chin-Sinex H, Shapiro JB, Imasuen-Williams IE, Rangel G, Gilley DP, et al: DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 112:318–326. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kendellen MF, Bradford JW, Lawrence CL, Clark KS and Baldwin AS: Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cells. Oncogene. 33:1297–1305. 2014. View Article : Google Scholar | |
|
Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG and Ethier SP: Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells. Mol Cancer Res. 5:847–861. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Saha S, Mukherjee S, Khan P, Kajal K, Mazumdar M, Manna A, Mukherjee S, De S, Jana D, Sarkar DK, et al: Aspirin suppresses the acquisition of chemoresistance in breast cancer by disrupting an NFkappaB-IL6 signaling axis responsible for the generation of cancer stem cells. Cancer Res. 76:2000–2012. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Watson PA, Arora VK and Sawyers CL: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, Srinivasan S, Nowak J, Izard T and Rangarajan ES: et al Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells. Mol Cell. 65:1122–1135.e1125. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Osborne CK and Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 62:233–247. 2011. View Article : Google Scholar | |
|
Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R and Isaacs WB: Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 67:470–479. 2015. View Article : Google Scholar | |
|
Crona DJ and Whang YE: Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel). 9:92017. View Article : Google Scholar | |
|
Lee JW, Kim GY and Kim JH: Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression. Biochem Biophys Res Commun. 420:428–433. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Penney RB and Roy D: Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer. Biochim Biophys Acta. 1836:60–79. 2013.PubMed/NCBI | |
|
Bakin RE, Gioeli D, Bissonette EA and Weber MJ: Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res. 63:1975–1980. 2003.PubMed/NCBI | |
|
Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M and Wu H: Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 72:1878–1889. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Heckler MM, Thakor H, Schafer CC and Riggins RB: ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer. FEBS J. 281:2431–2442. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hong SK, Jeong JH, Chan AM and Park JI: AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. Exp Cell Res. 319:1732–1743. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Zhang L, Fu Y, Fang F, Jiang Y, Dong Y and Zhu W: CSL regulates AKT to mediate androgen independence in prostate cancer progression. Prostate. 76:140–150. 2016. View Article : Google Scholar | |
|
Lu S, Ren C, Liu Y and Epner DE: PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells. Int J Oncol. 28:245–251. 2006. | |
|
Lee SO, Lou W, Nadiminty N, Lin X and Gao AC: Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate. 64:160–167. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez M, Luo W, Weng J, Zeng L, Yi Z, Siwko S and Liu M: PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF-κB. Oncogenesis. 3:e1142014. View Article : Google Scholar | |
|
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19:575–586. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK and Chi SG: Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene. 22:4314–4332. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Holloway JN, Murthy S and El-Ashry D: A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: The role of nuclear factor-kappaB. Mol Endocrinol. 18:1396–1410. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Tian M and Schiemann WP: TGF-beta stimulation of EMT programs elicits non-genomic ER-alpha activity and anti-estrogen resistance in breast cancer cells. J Cancer Metastasis Treat. 3:150–160. 2017. View Article : Google Scholar : | |
|
Penninkhof F, Grootegoed JA and Blok LJ: Identification of REPS2 as a putative modulator of NF-kappaB activity in prostate cancer cells. Oncogene. 23:5607–5615. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Brown NE, Paluch AM, Nashu MA, Komurov K and Waltz SE: Tumor cell autonomous RON receptor expression promotes prostate cancer growth under conditions of androgen deprivation. Neoplasia. 20:917–929. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
House CD, Jordan E, Hernandez L, Ozaki M, James JM, Kim M, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC, et al: NFkappaB promotes ovarian tumorigenesis via classical pathways that support proliferative cancer cells and alternative pathways that support ALDH(+) cancer stem-like cells. Cancer Res. 77:6927–6940. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Han B, Zhou B, Qu Y, Gao B, Xu Y, Chung S, Tanaka H, Yang W, Giuliano AE and Cui X: FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer. Oncogene. 37:1399–1408. 2018. View Article : Google Scholar : | |
|
Litchfield LM, Appana SN, Datta S and Klinge CM: COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells. Mol Cell Endocrinol. 382:358–367. 2014. View Article : Google Scholar | |
|
Rwigemera A, Mamelona J and Martin LJ: Inhibitory effects of fucoxanthinol on the viability of human breast cancer cell lines MCF-7 and MDA-MB-231 are correlated with modulation of the NF-kappaB pathway. Cell Biol Toxicol. 30:157–167. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel CF, Li W, Wu D, Miller JK, Sweeney C, Lazennec G, Fujisawa Y and Matsumura F: Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression. Arch Biochem Biophys. 512:78–86. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bekki K, Vogel H, Li W, Ito T, Sweeney C, Haarmann- Stemmann T, Matsumura F and Vogel CF: The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells. Pestic Biochem Physiol. 120:5–13. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shah KN, Wilson EA, Malla R, Elford HL and Faridi JS: Targeting ribonucleotide reductase M2 and NF-kappaB activation with didox to circumvent tamoxifen resistance in breast cancer. Mol Cancer Ther. 14:2411–2421. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yde CW, Emdal KB, Guerra B and Lykkesfeldt AE: NFkB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res Treat. 135:67–78. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Catz SD and Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 20:7342–7351. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Srinivasan S, Kumar R, Koduru S, Chandramouli A and Damodaran C: Inhibiting TNF-mediated signaling: A novel therapeutic paradigm for androgen independent prostate cancer. Apoptosis. 15:153–161. 2010. View Article : Google Scholar : | |
|
Liu VWS, Yau WL, Tam CW, Yao KM and Shiu SY: Melatonin inhibits androgen receptor splice variant-7 (AR-V7)-induced nuclear factor-kappa B (NF-kappaB) activation and NF-kappaB activator-induced AR-V7 expression in prostate cancer cells: Potential implications for the use of melatonin in castration-resistant prostate cancer (CRPC) therapy. Int J Mol Sci. 18:182017. View Article : Google Scholar | |
|
Zerbini LF, Wang Y, Cho JY and Libermann TA: Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res. 63:2206–2215. 2003.PubMed/NCBI | |
|
Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB and Lokeshwar BL: Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 67:6854–6862. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SO, Pinder E, Chun JY, Lou W, Sun M and Gao AC: Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate. 68:85–91. 2008. View Article : Google Scholar | |
|
Jeong JH, Park SJ, Dickinson SI and Luo JL: A constitutive intrinsic inflammatory signaling circuit composed of miR-196b, Meis2, PPP3CC, and p65 drives prostate cancer castration resistance. Mol Cell. 65:154–167. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
McCall P, Bennett L, Ahmad I, Mackenzie LM, Forbes IW, Leung HY, Sansom OJ, Orange C, Seywright M, Underwood MA, et al: NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. Br J Cancer. 107:1554–1563. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T and Eto M: Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer. Endocr Relat Cancer. 24:171–180. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pratt MAC, Bishop TE, White D, Yasvinski G, Menard M, Niu MY and Clarke R: Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: Roles in growth and hormone independence. Mol Cell Biol. 23:6887–6900. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S and Benz CC: Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer. 7:592007. View Article : Google Scholar : PubMed/NCBI | |
|
Semlali A, Oliva J, Badia E, Pons M and Duchesne MJ: Immediate early gene X-1 (IEX-1), a hydroxytamoxifen regulated gene with increased stimulation in MCF-7 derived resistant breast cancer cells. J Steroid Biochem Mol Biol. 88:247–259. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hu R, Warri A, Jin L, Zwart A, Riggins RB, Fang HB and Clarke R: NF-κB signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. Mol Cell Biol. 35:379–390. 2015. View Article : Google Scholar | |
|
Yamaguchi N, Nakayama Y and Yamaguchi N: Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. J Biol Chem. 292:8136–8148. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, et al: Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 73:3470–3480. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC and Clarke R: BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J. 24:2040–2055. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Riggins RB, Zwart A, Nehra R and Clarke R: The nuclear factor kB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther. 4:33–41. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q and Gao AC: Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res. 70:3309–3319. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nadiminty N, Chun JY, Lou W, Lin X and Gao AC: NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate. 68:1725–1733. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nadiminty N, Dutt S, Tepper C and Gao AC: Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate. 70:276–287. 2010. | |
|
Mehraein-Ghomi F, Church DR, Schreiber CL, Weichmann MA, Basu HS and Wilding G: Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated ARser81. Genes Cancer. 6:428–444. 2015.PubMed/NCBI | |
|
Nadiminty N, Tummala R, Liu C, Lou W, Evans CP and Gao AC: NF-kappaB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther. 14:1884–1895. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT and Gao AC: Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer. 21:435–442. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
House CD, Grajales V, Ozaki M, Jordan E, Wubneh H, Kimble DC, James JM, Kim MK and Annunziata CM: Ikke cooperates with either MEK or non-canonical NF-κB driving growth of triple-negative breast cancer cells in different contexts. BMC Cancer. 18:5952018. View Article : Google Scholar | |
|
Kim YR, Kim IJ, Kang TW, Choi C, Kim KK, Kim MS, Nam KI and Jung C: HOXB13 downregulates intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis. Oncogene. 33:4558–4567. 2014. View Article : Google Scholar | |
|
Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G and Bonavida B: Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 23:4993–5003. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, et al: Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res. 12:5578–5586. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai CH, Tzeng SF, Hsieh SC, Yang YC, Hsiao YW, Tsai MH and Hsiao PW: A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer. Sci Rep. 7:156242017. View Article : Google Scholar : PubMed/NCBI | |
|
Nathan S, Ma Y, Tomita YA, De Oliveira E, Brown ML and Rosen EM: BRCA1-mimetic compound NSC35446. HCl inhibits IKKB expression by reducing estrogen receptor-a occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells. Breast Cancer Res Treat. 166:681–693. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang L, Wang P, Sun YJ and Wu YJ: Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 38:2652019. View Article : Google Scholar | |
|
Coker-Gurkan A, Celik M, Ugur M, Arisan ED, Obakan-Yerlikaya P, Durdu ZB and Palavan-Unsal N: Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells. Amino Acids. 50:1045–1069. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Xiang S, Zhang Q, Wu J, Tang Q, Zhou J, Yang L, Chen Z and Hann SS: Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. J Exp Clin Cancer Res. 34:462015. View Article : Google Scholar | |
|
Xu Y, Fang F, St Clair DK, Josson S, Sompol P, Spasojevic I and St Clair WH: Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther. 6:2048–2056. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lundqvist J, Yde CW and Lykkesfeldt AE: 1a,25-dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells. Steroids. 85:30–35. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW and Weiss GR: NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol. 15:885–890. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA and Krasil'nikov MA: NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis. Mol Cell Biochem. 324:65–71. 2009. View Article : Google Scholar | |
|
Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, Noel T, Holley AK, Zhao Y, Kiningham KK, et al: KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res. 73:4406–4417. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Josson S, Xu Y, Fang F, Dhar SK, St Clair DK and St Clair WH: RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene. 25:1554–1559. 2006. View Article : Google Scholar | |
|
Tan C, Hu W, He Y, Zhang Y, Zhang G, Xu Y and Tang J: Cytokine-mediated therapeutic resistance in breast cancer. Cytokine. 108:151–159. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Khurana N and SIKKa SC: Targeting crosstalk between Nrf-2, NF-κB and androgen receptor signaling in prostate cancer. Cancers (Basel). 10:102018. View Article : Google Scholar | |
|
Ahmed KM, Zhang H and Park CC: NF-κB regulates radioresistance mediated by β1-integrin in three-dimensional culture of breast cancer cells. Cancer Res. 73:3737–3748. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chaturvedi MM, Sung B, Yadav VR, Kannappan R and Aggarwal BB: NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene. 30:1615–1630. 2011. View Article : Google Scholar | |
|
Lessard L, Begin LR, Gleave ME, Mes-Masson AM and Saad F: Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: An immunohistochemical study. Br J Cancer. 93:1019–1023. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Xu Z, Ding J, Tan C, Hu W, Li Y, Huang W and Xu Y: HZ08 suppresses RelB-activated MnSOD expression and enhances Radiosensitivity of prostate Cancer cells. J Exp Clin Cancer Res. 37:1742018. View Article : Google Scholar : PubMed/NCBI |
